A5101834946- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related gene regulation
- Psychosomatic Disorders and Their Treatments
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Mechanical Circulatory Support Devices
- Central Venous Catheters and Hemodialysis
- Hemostasis and retained surgical items
- Occupational Health and Performance
- CAR-T cell therapy research
- Total Knee Arthroplasty Outcomes
- Emergency and Acute Care Studies
- Cardiac tumors and thrombi
- Acute Myocardial Infarction Research
- Global Health Care Issues
- Agriculture and Farm Safety
- Knee injuries and reconstruction techniques
- Genital Health and Disease
- Potassium and Related Disorders
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Adolescent and Pediatric Healthcare
Rush University Medical Center
2005-2024
Rush University
2004-2022
Azienda Ospedaliera G. Brotzu
2020
Takeda (United States)
2016-2018
Baxalta (United States)
2018
Hospital Universitario La Paz
2016
Children's Hospital of Los Angeles
2006
University of Southern California
2006
Baxter (United States)
2006
Rush Children's Hospital
1996-2005
To compare results of low-dose tissue plasminogen activator (TPA) in children with arterial and venous thrombi relative to standard published dosing.Subjects consisted all consecutive objectively confirmed for whom TPA thrombolysis was clinically ordered by the authors. Initial dosing used dose (0.1-0.5 mg/kg per hour). With experience, a regimen (0.01-0.06 hour) given an attempt derive minimal effective dose.Thirty-five were treated TPA. Either or infusions resulted complete 28 29 (97%)...
Unlabelled Box<li>•Patients with hemophilia A and inhibitors receiving emicizumab experience breakthrough bleeding.</li><li>•Safety concerns may exist when combining bypassing agents.</li><li>•Combined agent bispecific antibody increased thrombin generation up to 17‐fold.</li><li>•Thrombotic effects should be considered plasma agent.</li> <h3>Summary: Background</h3> Investigational non‐factor products such as offer a treatment option for patients inhibitors. However, their mechanism of...
Haemophilia is a genetic disease as result of the deficiency blood coagulation factor VIII or IX. Bleeding common, especially into joints where an inflammatory, proliferative synovitis develops resulting in debilitating arthritis, haemophilic arthropathy. The pathogenesis blood-induced (HS) poorly understood. gross, microscopic and ultrastructural changes that occur synovial membrane following human experimental hemarthrosis have been described. Repeated episodes bleeding induce synoviocyte...
Arthropathy remains a major cause of morbidity in patients with haemophilia. Frequent bleeding into the joints leads to joint damage resultant contractures, deformities and arthritis. This turn muscle atrophy, limited physical activity, osteoporosis disability. Even though several studies prophylactic factor replacement for persons severe haemophilia demonstrate improved function, this therapy is still not readily available most people around world universal treatment protocol has been used....
Recurrent joint bleeding is the most common musculoskeletal manifestation of haemophilia and leads to a target synovitis. The pathobiology haemophilic synovitis (HS) not well understood. Here histopathological changes that occur following haemarthrosis were examined in an animal model for human HS. After two haemarthrosis, there was soft tissue swelling histological acute included infiltration sub-synovial layer by mononuclear cells neutrophils, thickening synovial membrane with villus...
Haemophilia A is an inherited, sex-linked disorder in which coagulation factor VIII (FVIII) deficient or absent [1]. The hallmark of the severe form disease, defined as plasma FVIII level <1% normal [2], early, recurrent bleeding into soft tissues and joints [3]. Intra-articular (haemarthrosis) accounts for more than 90% all serious events patients with haemophilia, 80% these bleeds involve knees, elbows ankles An acute haemarthrosis typified by rapid joint swelling that may be preceded a...
In a previous study [Psychother Psychosom 1994;61:199-204] we investigated the relationship between alexithymia, carcinogenesis and immunity in group of women who were unconscious sufferers from precancerous lesions cervix (CIN). The results this showed high level association alexithymia CIN and, an even more interesting fact, reduced levels immunity.The aim present is to check one by testing larger (43 affected cervical dysplasia 67 healthy women) use self-administered test for detection...
Alexithymia and circulating lymphocyte subsets were studied in 62 women [36 healthy 26 affected by cervical intraepithelial neoplasia (CIN I, II, III) who not aware of their status] order to assess a possible relationship between alexithymia, CIN immunological lymphocytic functions. was estimated the 20-item Schalling-Sifneos Personality Scale then correlated with peripheral blood subsets. The results our study report an association alexithymia CIN. Alexithymic show lower rates almost all...
Neonatal circumcision in patients with severe haemophilia has not been well studied. We performed a survey of paediatric haematologists from Hemophilia Treatment Centers (HTC) across the United States to better understand attitudes toward and management neonatal patients. Response rate our was 40% (n = 64/159). Thirty-eight percent respondents 24) said that they would allow this procedure newborn period but many cases against medical advice. The most reported concern regarding risk...
The development of an inhibitor represents one the most challenging complications in patients with haemophilia A. Optimal management is immune tolerance induction (ITI), typically through administration high doses factor VIII (FVIII) concentrate. Among 12 who underwent ITI using Advate, a third-generation recombinant FVIII product that free animal and human protein additives, was achieved nine (75%), including seven 10 (70%) high-titre inhibitors. ongoing two not yet successful; failed third...
ABSTRACT Introduction Evidence‐based clinical practice guidelines drive optimal patient care and facilitate access to high‐quality treatment. Creating for rare diseases such as haemophilia, where evidence does not often come from randomized controlled trials but non‐randomized well‐designed observational studies real‐world data, is challenging. The methodology used assessing available should consider this critical fact. In formulating guidelines, it essential include treatment goals...
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models Haemophilia Management, and ASH NBDF WFH guidelines diagnosis management VWD all utilised GRADE methodology. Aim Discuss missed opportunities methodological approach in contrast to how was previously applied rare diseases. Methods Critically analyse methodology each along with best practices use GRADE. Where applicable, Guidelines...
Summary. Preservation of normal joint function in patients with haemophilia is a goal modern therapy. Regular injections anti‐haemophilic factor concentrate reduce the risk bleeding, optimal regimen for which remains under investigation. The goals experiment described here are: (i) to assess capacity murine model severe haemophilic arthropathy predict likelihood success test product prevent bleeding and complications that follow (ii) compare effectiveness recombinant human activated VII...
Summary Prophylaxis may be beneficial for patients with severe haemophilia A who have developed inhibitors to factor VIII . The aim of this study was determine physicians' preferences medication attributes in the prophylactic treatment patient population. Haematologists from Europe ( EU ) and United States US participated a discrete choice exercise explore their (efficacy, cost, scientific evidence, dosing frequency administration time) associated prophylaxis Physicians' were assessed...
Introduction Contemporary haemophilia management recommends sport and physical activity in children with haemophilia. Assessment of subjective functioning requires standardized validated instruments. Aims To adapt psychometrically test the adult Haemophilia & Exercise Project‐Test‐Questionnaire (HEP‐Test‐Q) for (aged 6‐17 years). Methods In discussion rounds children, single items HEP‐Test‐Q were reformulated to make them understandable without changing item concept. The validation...